SCIENTIFIC ADVISORY BOARD
Dr. Frances A. Shepherd, M.D.
Full Professor of Medicine at the University of Toronto
Scott Taylor Chair in Lung Cancer Researc h at Princess Margaret Hospital
Dr. Shepherd received her M.D. from the University of Toronto in 1970 and currently is a senior staff physician at Princess Margaret Hospital in Toronto, Ontario, Canada where she holds the Scott Taylor Chair in Lung Cancer Research. She is a Full Professor of Medicine at the University of Toronto and served as the University Division Director for Medical Oncology for 6 years from 1997 to 2003.
Dr. Shepherd has been recognized for her many contributions in the field of lung cancer research, most notably her longstanding international leadership in the development of innovative therapies for lung cancer. In 2001 she was named the Scott Taylor Chair in Lung Cancer Research, becoming the first holder of this esteemed research position with a primary goal of investigating new options for lung cancer therapy. As Chair, Dr. Shepherd plays a vital role in attracting graduate students, scientists, other doctors and further research funding which will enable her team to intensify their study of lung cancer. Dr. Shepherd also serves as Chair of the Lung Cancer Site Committee of the National Cancer Institute of Canada Clinical Trials Group and is the immediate past President of the International Association for the Study of Lung Cancer, having served as president from 2003-2005. She was the recipient of the Jacqueline Seroussi Memorial Award for Cancer Research in 2004, The O Harold Warwick Award for Research Excellence of the National Cancer Institute of Canada in 2006 and the International Association for the Study of Lung Cancer Research Award in 2007. She received the Order of Ontario in 2007. Most recently in 2012, she was awarded the British Thoracic Oncology Group Award for Contributions to Lung Cancer Research.
Dr. Shepherd has been the co-investigator or principal investigator in over eighty trials since 1982. In 2002, she was a part of a team at Princess Margaret Hospital credited with the first identification of gene clusters that are involved in lung cancer using microarray technology that are involved in lung cancer. This work was funded by the National Cancer Institute of Canada. She was the senior investigator for the National Cancer Institute of Canada Clinical Trials Group BR.10 trial of adjuvant chemotherapy after surgery for non-small cell lung cancer, a study that showed that this form of therapy could improve survival at 5 years by 15%. She was also the Principal Investigator for the National Cancer Institute of Canada Clinical Trials Group BR.21 trial that led to the recent approval of erlotinib for patients with advanced non-small cell lung cancer who had received at least one regimen of chemotherapy. This international trial demonstrated that erlotinib, a new molecularly targeted therapy increased survival in advanced NSCLC patients who typically have no other treatment options. These two trials have changed treatment for early stage and advanced stage patients with lung cancer around the globe.
Dr. Shepherd has been instrumental in establishing Lung Cancer Tumour Banks in order to perform correlative science studies pertaining to lung cancer. Through her leadership, she has brought together a team of basic and clinical reaseachers committed to the evaluation of molecular pathways in lung cancer. This team is recognized world-wide as one of the foremost groups of bench to bedside research pertaining to lung cancer.
Dr. Shepherd has served as the Chair of the American Society of Clinical Oncology Membership and Publications Committees. Currently, she is on the Board of Directors of the American Society of Clinical Oncology and the European Organization for Research and Treatment of Cancer. She also chairs the Protocol Review Committee of the European Organization for Research and Treatment of Cancer. She sits on numerous national and international Lung Cancer Advisory Boards, and chairs and/or sits on several Data and Safety Monitoring Boards for international lung cancer trials in Europe and North America. She has authored 385 peer reviewed publications and 35 book chapters.